| 1 |
|
Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada
|
Goodman, M.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 2 |
|
Can Isis Remain A Platform Company?
|
Goodman, M.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 3 |
|
Can MDCO Make Alnylam's PCSK9 Candidate Work In The Hospital? Lagging the antibodies, The Medicine's Co.'s novel approach to the PCSK9 race brings certain strenghts, not the least being a fundamentally different mechanism. Moreover, being last may not be least in a field that's changing as rapidly as lipidology
|
Goodman, M.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 4 |
|
Dedication: Shneior Lifson/
|
Goodman, M
|
John Wiley ＆ Sons, etc.]
|
2003
|
|
|
|
| 5 |
|
Editorial - Editorial: Dynamic Database Linking in Biopolymers Published online 27 September 2001/
|
Goodman, M
|
John Wiley ＆ Sons, etc.]
|
2002
|
|
|
|
| 6 |
|
Epizyme Builds A Cancer Company At Mach Speed: Epizyme's recent alliance with Celgene validates industry's interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene's willingness to cede US rights in return for access to preclinical assets belies HMTs' novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won't be easy
|
Goodman, M.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 7 |
|
Hemophilia In Transition: Can Next-Gen Products Wake A Sleepy Market?: Over the next three years, long-acting factor products may have a transformative effect on the hemophilia market, but will the improvements be enough to sway providers and payors?
|
Goodman, M.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 8 |
|
How And Why Genzyme And Alnylam Expanded Their Alliance
|
Goodman, M.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 9 |
|
New Reagents, Reactions, and Peptidomimetics for Drug Design Published online 14 December 2001/
|
Goodman, M
|
John Wiley ＆ Sons, etc.]
|
2001
|
|
|
|
| 10 |
|
Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?
|
Goodman, M.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 11 |
|
People Power: How The Crowd May Shape The Funding And Development Of Drugs
|
Goodman, M.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 12 |
|
Personalized Medicine Takes Aim At Common Diseases
|
Goodman, M.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 13 |
|
Takeda's Strategic Run Up To Nycomed
|
Goodman, M.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 14 |
|
Temporal relationship modeling: DTP or DT immunizations and infantile spasms
|
Goodman, M
|
Butterworths
|
1998
|
|
|
|
| 15 |
|
The Alnylam Turnaround: What Changed Investors' Minds?
|
Goodman, M.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 16 |
|
When Opportunity Knocks: Eisai Turns To Business Development: Starting in 2006, Eisai embarked on a bold campaign to reorient the company around cancer, with an emphasis on externally sourced innovation. This put aggressive BD front and center. Now as Eisai prepares to launch what may be its most transformative in-licensed product, the weight-loss therapy Belviq, signs of trouble have appeared in its trophy cancer franchise
|
Goodman, M.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 17 |
|
Xalkori And The Art Of Modern Drug Development
|
Goodman, M.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
기사
(17)
